Asagiri Masataka, Hirai Toshitake, Kunigami Toshihiro, Kamano Shunya, Gober Hans-Jürgen, Okamoto Kazuo, Nishikawa Keizo, Latz Eicke, Golenbock Douglas T, Aoki Kazuhiro, Ohya Keiichi, Imai Yuuki, Morishita Yasuyuki, Miyazono Kohei, Kato Shigeaki, Saftig Paul, Takayanagi Hiroshi
Department of Cell Signaling, Graduate School, Tokyo Medical and Dental University, Tokyo 113-8549, Japan.
Science. 2008 Feb 1;319(5863):624-7. doi: 10.1126/science.1150110.
Cathepsin K was originally identified as an osteoclast-specific lysosomal protease, the inhibitor of which has been considered might have therapeutic potential. We show that inhibition of cathepsin K could potently suppress autoimmune inflammation of the joints as well as osteoclastic bone resorption in autoimmune arthritis. Furthermore, cathepsin K-/- mice were resistant to experimental autoimmune encephalomyelitis. Pharmacological inhibition or targeted disruption of cathepsin K resulted in defective Toll-like receptor 9 signaling in dendritic cells in response to unmethylated CpG DNA, which in turn led to attenuated induction of T helper 17 cells, without affecting the antigen-presenting ability of dendritic cells. These results suggest that cathepsin K plays an important role in the immune system and may serve as a valid therapeutic target in autoimmune diseases.
组织蛋白酶K最初被鉴定为破骨细胞特异性溶酶体蛋白酶,其抑制剂被认为可能具有治疗潜力。我们发现,抑制组织蛋白酶K可有效抑制关节的自身免疫炎症以及自身免疫性关节炎中的破骨细胞骨吸收。此外,组织蛋白酶K基因敲除小鼠对实验性自身免疫性脑脊髓炎具有抗性。对组织蛋白酶K的药理抑制或靶向破坏导致树突状细胞中Toll样受体9信号在响应未甲基化CpG DNA时出现缺陷,进而导致辅助性T细胞17细胞的诱导减弱,而不影响树突状细胞的抗原呈递能力。这些结果表明,组织蛋白酶K在免疫系统中起重要作用,可能是自身免疫性疾病的有效治疗靶点。